Triple Negative Breast Cancer Chemotherapy Response Calculator

Oncology and Hematology
Clinical and Translational Investigation in Cancer

Triple-negative breast cancer (TNBC) is characterised by high pathological complete response to neoadjuvant chemotherapy (NAC). However, refractory and poor NAC responders still face very poor outcome, emphasising the urgent need for tools that facilitate identification of these patients, so that surgery or alternatives to NAC are considered early in the treatment protocol.

Click here to access Chemotherapy Response Calculator

Triple Negative Breast Cancer Chemotherapy Response Calculator is intended to be used for research purposes only, without any medical objective.

Our findings demonstrate that the suppressive pathways of the immune system play a key role in modulating the NAC response in TNBC. We identify a crosstalk mechanism between tumour cells and eMDSCs that exacerbates immunosuppression. These results provide a potential new tool to identify poor NAC responders for alternative strategies of treatment, including early surgical resection of the tumour, and to explore in them alternative immune therapies.


Salvador-Coloma C, Santaballa A, Sanmartin E, Calvo D, García C, Hervás D, Cordón L, Quintas G, Ripoll F, Panadero J and Font de Mora J. (2020). "Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer". Eur. J. Cancer. 139:119-134. Enlace.